Linda Young
Nurse Practitioner · Lincoln, RINPI 1184776080
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,122 of the $18,641 with a category attached, or 65.0%. 26 manufacturers reported payments, led by Indivior Inc. at 55.4% of the total. 2025 is the largest year on record at $10,569, more than ten times the $590 reported in 2021. Among nurse practitioner clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $90.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$10K
- Phathom Pharmaceuticals, Inc.$6K
- AstraZeneca$444
- AbbVie$272
- Amgen$237
- Exact Sciences$234
- plus $1K from 20 others
What the payments were for
- Consulting fees$7184%
- Speaking & faculty fees$12,12265%
- Travel & lodging$1,5708%
- Food & beverage$4,12322%
- Education$1091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 41 | $10,325 |
| Phathom Pharmaceuticals, Inc. | 31 | $5,867 |
| AstraZeneca | 21 | $444 |
| AbbVie | 13 | $272 |
| Amgen | 14 | $237 |
| Exact Sciences | 12 | $234 |
| Lundbeck LLC | 12 | $196 |
| Amarin Pharma, Inc. | 17 | $170 |
| Novo Nordisk | 7 | $123 |
| Astellas Pharma US Inc | 2 | $121 |
| Pfizer | 6 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $101 |
| Abbott | 5 | $91 |
| Biodelivery Sciences International, Inc. | 4 | $51 |
| Novartis | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $35 |
| Acella Pharmaceuticals, LLC | 2 | $31 |
| Lilly USA, LLC | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Corium, LLC | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,641 in reported general payments places this provider in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $52,476 |
| EliquisApixaban | 40 | $41,908 |
| OxycontinOxycodone Hcl | 24 | $27,396 |
| TrintellixVortioxetine Hydrobromide | 16 | $11,551 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,335 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $10,687 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 59 | $10,221 |
| JardianceEmpagliflozin | 17 | $9,933 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $4,451 |
| Atorvastatin Calcium | 282 | $3,113 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $2,972 |
| Lidocaine | 28 | $2,473 |
| Omeprazole | 186 | $2,471 |
| Candesartan Cilexetil | 17 | $2,219 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $2,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $123 | $52,47648 claims |
| PfizerEliquis | $114 | $41,90840 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $36 | $11,55116 claims |
| AstraZenecaBreztri Aerosphere | $444 | $11,33518 claims |
| Indivior Inc.Suboxone | $10,325 | $10,68713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Other nurse practitioner in Lincoln
- Nicholas ChasseLincoln$3K
- Ruth ChevezLincoln$2K
- Victoria VoshchinLincoln$409
- Lynne GlaserCumberland$17K
- Stephanie CostaWarwick$9K
- Maria SilvaJohnston$7K
- Natalie DriscollMiddletown$6K
- Lea KellyProvidence$5K
- Kathleen ParkerWarwick$5K
- Priscilla PonteEast Providence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.